News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Odronextamab plus chemo safe as DLBCL treatment, with promising efficacy
16 Jan 2026
byStephen Padilla
Combination treatment with the CD20×CD3 bispecific antibody odronextamab and chemotherapy is generally safe among previously untreated diffuse large B cell lymphoma (DLBCL) patients, without new safety signals, as shown by the results from part 1 of the phase III Olympia-3 study.








